1. Introduction {#sec1}
===============

The clinical high-risk state of psychosis (at-risk mental state, hereafter ARMS) is defined by attenuated positive psychotic symptoms, genetic liability and functional deterioration or brief and self-remitting psychotic symptoms ([@ref19]; [@ref63]). However, affective symptoms, including depressive and anxiety symptoms, are also highly prevalent in these individuals ([@ref45]). A recent meta-analysis, conducted in 1683 high-risk subjects, confirmed that the baseline prevalence of comorbid depressive and anxiety disorder is 41% and 15%, respectively ([@ref20]). Depressive and anxiety symptoms can precede the onset of attenuated positive psychotic symptoms ([@ref19]). Some studies indicate that co-occurrence of depressive disorders can predict subsequent transition to psychosis in ARMS individuals ([@ref45]). However, other studies have not confirmed this finding ([@ref20]). Additionally, a large study on 3349 twins suggests an association between depressive and/or anxiety symptoms and psychosis-like traits (schizotypy) and emphasizes a major role for genetics, especially as regards positive symptoms ([@ref36]). The comorbidity of psychotic and depressive disorders in the ARMS population is associated with specific psychopathological features at the time of the presentation to high risk services and with low functional level ([@ref19]). Because of these problems, clinical high-risk individuals often receive antidepressant medication (e.g. 42% of ARMS individuals in our previous study ([@ref48])).

Negative psychotic symptoms are a major source of disability in the psychosis spectrum and are refractory to any effective treatment ([@ref21]). Negative symptoms group into two factors, one involving diminished expression of affect and alogia and the second involving avolition, including anhedonia and asociality ([@ref21]). Antidepressants may have a potential benefit for ARMS individuals, as they may target their negative attenuated psychotic symptoms ([@ref15]; [@ref23]). These studies indicate that antidepressant treatments in ARMS individuals can impact their longitudinal outcomes. However, it is not clear if these improvements are associated with underlying neurobiological changes ([@ref62]).

Neuroimaging studies using magnetic resonance imaging (MRI) have indicated that ARMS showed brain alterations in the prefrontal ([@bb9000]; [@ref10]; [@ref29]; [@ref38]; [@ref61]), cingulate ([@ref18]; [@ref29]), superior ([@ref51]; [@ref52]) and medial temporal ([@ref11]; [@ref54]), insular ([@ref49]) and cerebellar regions when compared to healthy controls. Furthermore, ARMS individuals with subsequent transition to psychosis showed volumetric reductions in the prefrontal, insular and cingulate cortex compared to those without transition ([@ref49]).

Similar alterations were found in depressive disorders. Reductions in gray matter volume (GMV) in the anterior cingulate gyrus, hippocampus, amygdala ([@ref28]) and prefrontal cortex ([@ref34]) were associated with major depression. The only available study directly testing the effect of comorbid depressive disorders on the neurobiology of ARMS uncovered a significant impact on the anterior cingulate region ([@ref39]). On the other hand, long-term antidepressant medication can be neuroprotective and some studies have linked the use of antidepressants to an increase in hippocampal volume in patients with major depressive disorder ([@ref2]; [@ref37]). It has been shown that antidepressants increase hippocampal neurogenesis ([@ref3]). Thus, both affective symptoms ([@ref7]) and antidepressant medication ([@ref30]) are known to impact brain structure.

In the present study, we addressed for the first time the effect of antidepressant treatment and attenuated negative psychotic symptoms on the neurobiology of ARMS. Firstly, we hypothesized that ARMS individuals without current antidepressant treatment (ARMS-nonAD) would manifest more severe attenuated negative symptoms than ARMS subjects currently receiving antidepressants (ARMS-AD). Secondly, we hypothesized that ARMS-AD individuals would have increased GMV in regions associated with depressive symptoms and/or antidepressant medication (hippocampus, anterior cingulate gyrus, amygdala and precuneus) compared to the ARMS-nonAD individuals. Thirdly, we hypothesized that the volumetric abnormalities in gray matter between ARMS-AD and ARMS-nonAD would be associated with attenuated negative symptoms.

2. Materials and methods {#sec2}
========================

2.1. Subjects {#sec2.1}
-------------

MRI data were collected within the framework of a research program on the early detection of psychosis. The subjects were recruited in our specialized clinic for the early detection of psychosis (FEPSY) at the Psychiatric Outpatient Department, Psychiatric University Clinics Basel, Switzerland ([@ref44]).

The entire group of ARMS individuals (n = 49) conforms to Yung\'s criteria ([@ref63]) and overlaps with previously published data ([@ref9]; [@ref11]; [@ref48]; [@ref50]). All the ARMS individuals were antipsychotic-free and were assessed prior to the neuroimaging session. ARMS inclusion required one or more of the following:(a)attenuated psychotic symptoms that do not reach full psychosis threshold(b)brief limited intermittent psychotic symptoms (lasting less than a week with spontaneous remission)(c)a first degree relative with a psychotic disorder plus at least two indicators of a clinical change, such as a marked decline in social or occupational functioning.

We assessed the subjects using the Basel Screening Instrument for Psychosis (BSIP) ([@ref43]), the Brief Psychiatric Rating Scale (BPRS) ([@ref35]), the Scale for the Assessment of Negative Symptoms (SANS) ([@ref5]) and the Global Assessment of Functioning (GAF) ([@ref17]). Attenuated negative psychotic symptom severity was investigated with the cluster 'negative symptoms', calculated from the BPRS as a sum of blunted affect, emotional withdrawal, and motor retardation (BPRS16, BPRS17 and BPRS18) ([@ref21]; [@ref56]). Additionally, we calculated 'mood disturbance' BPRS cluster as a sum of anxiety, depression, suicidality and guilt (BPRS02, BPRS03, BPRS04 and BPRS05) ([@ref53]), as well as depression (BPRS03) and motor retardation (BPRS18) scores alone. We used these scores for stepwise regression analysis with backward elimination.

In a second step, we divided the ARMS individuals into two subgroups, based on whether they were currently being treated with antidepressants (ARMS-AD, n = 18) or not (ARMS-nonAD, n = 31) ([Table 1](#t0005){ref-type="table"}). Antidepressant medication within the AD subgroup included: fluoxetine (SSRI; n = 2), escitalopram (SSRI; n = 5), sertraline (SSRI; n = 1), mirtazapine \[NaSSA (noradrenergic and specific serotonergic antidepressant); n = 4\], venlafaxine \[SSNRI (selective serotonin--norepinephrine reuptake inhibitor), n = 2\], duloxetine (SSNRI; n = 2), fluoxetine plus trazodone \[SSRI, SARI (serotonin antagonist and reuptake inhibitor); n = 1\] and St. John\'s Wort (n = 1). Antidepressant therapy had a mean duration of 50 ± 47 days (range 4--170 days). In order to exclude possible biases through antipsychotic therapy, we confirmed that all individuals were antipsychotic-free. In addition, current and previous psychotropic medication, alcohol, nicotine, cannabis, and other illegal drug consumption were assessed using a semi-structured interview, as adapted from the Drug and Alcohol Assessment Schedule of the Early Psychosis Prevention and Intervention Centre (EPPIC).

Participants were excluded from the study if they presented with a history of previous psychotic disorder, psychotic symptomatology secondary to an organic disorder, substance abuse, affective psychosis, borderline personality disorder, age under 18 or over 40, inadequate knowledge of the German language or IQ less than 70 (assessed by multiple-choice vocabulary intelligence test) ([@ref33]).

Healthy controls (n = 24) were from the same geographical area as the other groups ([Table 1](#t0005){ref-type="table"}). All participants provided written informed consent. The study was approved by the local ethics committee.

2.2. Magnetic resonance imaging acquisition {#sec2.2}
-------------------------------------------

For structural imaging, a whole brain 3D T~1~-weighted MPRAGE (magnetization prepared rapid acquisition gradient) sequence was applied using a 3 T magnetic resonance imaging scanner (Magnetom Verio, Siemens Healthcare, Erlangen, Germany) and a 12-channel radio frequency head coil. The acquisition was based on a sagittal matrix of 256 × 256 × 176 and 1 × 1 × 1 mm^3^ isotropic spatial resolution, with an inversion time of 1000 ms, repetition time of 2 s, echo time of 3.4 ms, flip angle of 8° and bandwidth of 200 Hz/pixel. All images were reviewed by trained neuroradiologists for radiological abnormalities.

2.3. Image analysis {#sec2.3}
-------------------

Structural MRI data were analyzed using the voxel-based morphometry toolbox (VBM8, [[http://dbm.neuro.uni-jena.de/vbm8/]{.ul}](http://dbm.neuro.uni-jena.de/vbm8/){#interref1}), implemented within SPM8 (Wellcome Department of Cognitive Neurology, London, UK) and running on Matlab 7.11 (MathWorks, USA). All T~1~-weighted images were first checked for scanner artifacts and anatomical abnormalities. Images were then segmented into gray matter, white matter and cerebrospinal fluid using the adaptive maximum a posteriori technique (in contrast to the classical use of a priori Tissue Probability Maps), where local variations in the parameters are modeled by means of slowly varying spatial functions ([@ref41]). More accurate segmentation can be achieved with partial volume estimation of additional mixed tissue classes in every voxel. All images were DARTEL-normalized (Diffeomorphic Anatomical Registration using Exponentiated Lie algebra; [@ref6]). The DARTEL template was derived from 550 healthy controls as provided in MNI space. This method produces more accurate results for registration and additional registration in MNI space was unnecessary ([@ref6]). Finally, sample homogeneity was reviewed and all images were smoothed using an *isotropic 8 mm full-width-at-half-maximum* (FWHM) Gaussian kernel ([@ref47]).

Group differences were explored using a one-way ANOVA. Since our groups differed significantly in gender and age, we introduced these two variables as additional covariates of interest. Group comparisons included ARMS-AD versus ARMS-nonAD versus healthy controls. Brain region labeling was achieved using the Harvard--Oxford structural atlas ([[http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/Atlases]{.ul}](http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/atlases){#interref2} ([@ref16])), incorporated within the FMRIB Software Library (FSL).

Statistical significance was assessed at a cluster level using a threshold of p \< 0.005 *uncorrected* (cluster-forming threshold); statistical inference was then made at p \< 0.05, adjusted to provide a family-wise error (FWE) correction at the peak and cluster levels.

2.4. ROI analysis {#sec2.4}
-----------------

On the basis of the previous evidence, we defined 4 specific regions of interest (ROIs) to test for differences in GMV between our two ARMS groups: the bilateral hippocampus, (associated with greater risk of depressive disorder; [@ref2]; [@ref55]), the anterior cingulate gyrus (reported to be reduced during ongoing depression; [@ref2]; [@ref28]) and in co-morbid depression in ARMS ([@ref39]); the amygdala (inconsistent changes in depression; [@ref28]) and the precuneus (associated with increased gray matter density after short antidepressant application in HC; [@ref30]).

All the regions were *individually* defined using the Wake Forest University PickAtlas Toolbox ([[http://fmri.wfubmc.edu/software/PickAtlas]{.ul}](http://fmri.wfubmc.edu/software/pickatlas){#interref3}). For each region, a small volume correction was conducted using a 5 mm radius for the hippocampus ([@ref2]; [@ref55]) and amygdala or a 10 mm radius for the precuneus and anterior cingulate cortex (ACC) ([@ref1]; [@ref2]).

Mean gray matter volume indices were extracted from these regions using the Rex Toolbox ([[http://web.mit.edu/swg/software.htm]{.ul}](http://web.mit.edu/swg/software.htm){#interref4}) implemented in Matlab 7.11. The analysis was performed on region of interest basis, with *no conjunction mask*, *no scaling* and extraction of the *mean* within the predefined ROI. The extracted values were used for a stepwise backward regression analysis (see [Supplementary table](#ec0005){ref-type="supplementary-material"}). Only corrected family-wise error values were taken into consideration, in order to avoid a type I error.

Mean gray matter volume indices were extracted from these regions using the Rex Toolbox ([[http://web.mit.edu/swg/software.htm]{.ul}](http://web.mit.edu/swg/software.htm){#interref5}) implemented in Matlab 7.11. The analysis was performed on region of interest basis, with *no conjunction mask*, *no scaling* and extraction of the *mean* within the predefined ROI. The extracted values were used for a stepwise backward regression analysis (see Supplementary table). Only corrected family-wise error values were taken into consideration, in order to avoid a type I error.

2.5. Statistical analysis of clinical variables {#sec2.5}
-----------------------------------------------

Clinical and socio-demographic differences were assessed using one-way ANOVA and χ^2^-test. For post hoc analysis, the Bonferroni correction was conducted. In addition, a stepwise regression analysis with backward elimination was applied, to restrict correlating variables. We included the BPRS total score and SANS total score; as well as the BPRS clusters for 'negative symptoms' as a sum of blunted affect, emotional withdrawal, and motor retardation (BPRS16, BPRS17 and BPRS18); and 'mood disturbance' as a sum of anxiety, depression, suicidality and guilt (BPRS02, BPRS03, BPRS04 and BPRS05); and the single scores 'depression' (BPRS 3) and 'motor hyperactivity' (BPRS 23) (see [Supplementary table](#ec0005){ref-type="supplementary-material"}). We applied outlier detection using Cook\'s Distance Test and no subject had to be excluded from regression analysis. Still, we excluded one ARMS-nonAD individual due to missing data in the BPRS 16, 17, and 18 necessary for calculating the cluster 'negative symptoms'. We then performed a correlation with our significant clinical parameters from the stepwise regression. From the regions of interest with significant differences between ARMS-AD and ARMS-nonAD (hippocampus and precuneus), we extracted the volumes and used them in our in correlation calculations. The data were normally distributed and we performed a series of two-tailed Pearson\'s correction analyses with statistical threshold set at p \< 0.05. All analyses were performed using the Statistical Package for the Social Science (SPSS, Version 22).

Clinical and socio-demographic differences were assessed using one-way ANOVA and χ^2^-test. For post hoc analysis, the Bonferroni correction was conducted. In addition, a stepwise regression analysis with backward elimination was applied, to restrict correlating variables. We included the BPRS total score and SANS total score; as well as the BPRS clusters for 'negative symptoms' as a sum of blunted affect, emotional withdrawal, and motor retardation (BPRS16, BPRS17 and BPRS18); and 'mood disturbance' as a sum of anxiety, depression, suicidality and guilt (BPRS02, BPRS03, BPRS04 and BPRS05); and the single scores 'depression' (BPRS 3) and 'motor hyperactivity' (BPRS 23) (see Supplementary table). We applied outlier detection using Cook\'s Distance Test and no subject had to be excluded from regression analysis. Still, we excluded one ARMS-nonAD individual due to missing data in the BPRS 16, 17, and 18 necessary for calculating the cluster 'negative symptoms'. We then performed a correlation with our significant clinical parameters from the stepwise regression. From the regions of interest with significant differences between ARMS-AD and ARMS-nonAD (hippocampus and precuneus), we extracted the volumes and used them in our in correlation calculations. The data were normally distributed and we performed a series of two-tailed Pearson\'s correction analyses with statistical threshold set at p \< 0.05. All analyses were performed using the Statistical Package for the Social Science (SPSS, Version 22).

3. Results {#sec3}
==========

3.1. Clinical and demographic characteristics {#sec3.1}
---------------------------------------------

The ARMS-AD, ARMS-nonAD and HC showed significant differences in age at MRI scan (p = 0.02), gender (p = 0.01), years of education (p = 0.002), smoking (p = 0.001), and cannabis (p = 0.006); but no differences in alcohol consumption or handedness. Post hoc analysis showed that smoking (p = 0.006) and cannabis consumption (p = 0.014) were significantly more common in the ARMS-AD group than in the ARMS-nonAD group ([Table 1](#t0005){ref-type="table"}).

We observed significant clinical differences between ARMS-AD, ARMS-nonAD and HC in the total BPRS score (p \< 0.0001), total SANS score (p \< 0.0001), GAF total score (p \< 0.0001), BPRS cluster for 'negative symptoms' (p \< 0.0001), BPRS 'mood disturbance' (p \< 0.0001), BPRS 'depression' score (p \< 0.0001), and BPRS 'motor hyperactivity' score (p = 0.005). Post hoc analysis showed that the ARMS-AD had a higher BPRS 'depression' score (p = 0.011) and less 'motor hyperactivity' (p = 0.029) than the ARMS-nonAD ([Table 1](#t0005){ref-type="table"}). The test of our a priori defined contrast in attenuated negative symptoms (BPRS cluster for 'negative symptoms') between ARMS-nonAD and ARMS-AD found no significant difference (p = 0.220).

3.2. Whole brain analysis {#sec3.2}
-------------------------

Compared to the HC, there was significantly less GMV in the middle frontal gyrus in the whole ARMS cohort, and in the superior frontal gyrus in the ARMS-AD group (p~uncorr.~ \< 0.05, [Table 2](#t0010){ref-type="table"}).

The ARMS-nonAD group showed reduced GMV in the left superior parietal lobe compared with the ARMS-AD group (p~uncorr.~ \< 0.05, [Table 2](#t0010){ref-type="table"}).

3.3. Region of interest analyses {#sec3.3}
--------------------------------

The ARMS-AD group had less GMV in the left hippocampus ([Fig. 1](#f0005){ref-type="fig"}) and right precuneus than the ARMS-nonAD (p~FWE-corr.~ \< 0.05 after small volume correction, [Table 2](#t0010){ref-type="table"}). However, these results did not survive correction for multiple comparisons (p \< 0.0125). No significant differences were found for the ACC and amygdala.

3.4. Correlation between ROI volumes and clinical parameters {#sec3.4}
------------------------------------------------------------

We found a negative correlation between the hippocampal volume and the BPRS 'negative symptoms' cluster, both in ARMS subjects (r = −0.314, p = 0.030, [Fig. 2](#f0010){ref-type="fig"}) and in all our subjects, including the HC (r = −0.293, p = 0.013).

There was no significant correlation between the BPRS 'negative symptoms' and the precuneus volume.

4. Discussion {#sec4}
=============

In the present study, we addressed for the first time the effect on psychosis of antidepressant treatment and attenuated negative psychotic symptoms in ARMS individuals.

Firstly, we have found no evidence for our first hypothesis, that ARMS individuals suffer more pronounced attenuated negative psychotic symptoms if they have not been treated with antidepressants.

We found that ARMS-AD individuals had a higher depression score, lower motor hyperactivity and smoked more cigarettes and marijuana than the ARMS-nonAD individuals. The antidepressants that ARMS-AD individuals were receiving differed in their mode of action -- some inhibited the reuptake of serotonin and/or noradrenaline, while others enhanced the release of these monoamines ([@ref4]). Moreover, the antidepressants may take weeks or longer to take effect after dosage ([@ref40]). The duration of antidepressant therapy in the ARMS-AD group varies from 4 to 170 days and thus the observed effect could be indicative of both the predominant depressive and/or attenuated negative psychotic symptoms or of the already developed antidepressant effect of the medication. Hence, we cannot clearly distinguish the extent to which each of the two components contributes to the current clinical state.

Secondly, we did not find increased GMV in the regions associated with depressive symptoms in those ARMS who were receiving antidepressants, compared to those without this medication. Thus we could not confirm our second hypothesis, but found GMV deficits in the hippocampus and precuneus only in the ARMS individuals currently receiving antidepressant medication.

Our third hypothesis is related to the volumetric abnormalities in ARMS and their association with the attenuated negative symptoms; we confirmed this relationship in the hippocampus. We found a clear negative correlation between the bilateral hippocampal volume and attenuated negative symptoms in all ARMS individuals.

This corresponds to studies linking the hippocampus with psychosis ([@ref26]). Previous studies similarly either found negative correlations between the left hippocampal volume and negative symptoms in schizophrenics ([@ref42]), or at least a strong trend in this direction ([@ref12]). These findings underline the role of the hippocampus in the pathophysiology of schizophrenia and suggest specific associations between individual structures and both the positive and negative symptoms of the illness ([@ref32]; [@ref42]). Thus, our findings support the importance of hippocampal structures as a region of interest in the early stage of psychosis ([@ref8]; [@ref22]; [@ref58]).

Our ROI analysis demonstrated smaller GMV in the left hippocampus in the ARMS-AD group than in the ARMS-nonAD group. The hippocampus is involved in various psychiatric conditions, including major depression and psychosis ([@ref57]; [@ref58]). Three meta-analyses have confirmed significant reductions in the hippocampal volume in depression ([@ref13]; [@ref14]; [@ref57]). Furthermore, the total number of depressive episodes was significantly correlated to the reduction in the right hippocampal volume ([@ref57]). The left-hemispheric deficits in hippocampal volume may reflect brain degeneration, as a consequence of chronic stress ([@ref46]). Recent data on antipsychotic-free ARMS have confirmed that vulnerability to psychosis may be associated with a significant decrease in hippocampal volume ([@ref22]; [@ref61]).

In the right precuneus, we found less GMV in the ARMS-AD group than in the ARMS-nonAD group. This is consistent with Grieve et al. ([@ref25]), who found significant reductions in the precuneus volumes, along with several other structural changes in depression. However, the direction of the effect is controversial. For example, a positive association was described between the volume of the precuneus and the severity of depression ([@ref31]). It is well established that intrusive imagery and increased self-focus, common in patients suffering from depression, are regularly associated with higher depression scores ([@ref31]). Since the precuneus is involved in visuospatial processing, imagery and self-related processing ([@ref27]; [@ref60]), depression could in principle enhance its GMV.

We acknowledge the limitations of a cross-sectional design, which precludes studying clinical and structural abnormalities within the same group of ARMS before and after antidepressant medication. In order to decide whether brain volumetric deficits are related to distinct depressive symptoms or to the antidepressant effect, longitudinal study designs are needed. Secondly, other confounders, such as nicotine and cannabis consumption, may have influenced our findings (higher consumption in ARMS-AD individuals). Furthermore, the ARMS-nonAD group shows more motor hyperactivity than the ARMS-AD group. This could result from the early effect of the antidepressant medication or from the sedative effect of cannabis or nicotine self-medication, which was higher in the ARMS-AD group ([@ref59]). Cigarette use may serve as an instrument to alleviate depressive symptoms, although the role of cannabis consumption is unclear. We can only speculate that the attenuated negative symptoms may drive cannabis consumption, although this abuse may exacerbate the positive symptoms observed ([@ref24]). We are also aware that not all negative symptoms are of hippocampal origin. In addition, the prescribed antidepressant drugs have different affinities to various synaptic receptors and therefore their effects on macroscopic structures and neurogenesis may vary and also be associated with other brain regions. Likewise, differences in the duration of antidepressant therapy may affect their impact on brain structure. Finally, relatively small sample groups are included, which reduces the statistical power to detect any significant effects.

5. Conclusion {#sec5}
=============

Hippocampal volume was negatively associated with attenuated negative psychotic symptoms in ARMS individuals. Surprisingly, ARMS individuals without antidepressant medication did not suffer more pronounced attenuated negative psychotic symptoms. The short-term antidepressant medication in this study is more likely to be an indicator of a more serious depressed state than to have a direct effect on attenuated negative psychotic symptoms. These findings emphasize the importance of comorbidity issues, especially in the context of depressive and attenuated negative psychotic symptoms in clinical high-risk individuals and their functional outcomes.

The following are the supplementary data related to this article.SupplementStepwise regression analysis with backward elimination.

Supplementary material for this article can be found online at [http://dx.doi.org/10.1016/j.nicl.2015.04.016](10.1016/j.nicl.2015.04.016){#ir0020}.

![Reductions in gray matter volume are associated with more severe depression. ARMS-AD individuals show less gray matter volume in the left hippocampus than ARMS-nonAD.](gr1){#f0005}

![Attenuated negative psychotic symptoms are associated with hippocampal volume. 'BPRS negative symptoms' correlate negatively with the bilateral hippocampus volume in all included ARMS subjects. The shaded area indicates the 95% CI of the fitted regression line. 'BPRS negative symptoms' score is a sum of blunted affect, emotional withdrawal, and motor retardation (BPRS16, BPRS17 and BPRS18). Hippocampal volume was extracted as mean gray matter volume in arbitrary units using Rex Toolbox.](gr2){#f0010}

###### 

Demographic and clinical data.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------
  Characteristic                   ARMS-AD (n = 18)   ARMS-nonAD (n = 31)   HC (n = 24)    Statistic                Post hoc[\*](#tf0005){ref-type="table-fn"}
  -------------------------------- ------------------ --------------------- -------------- ------------------------ -----------------------------------------------
  Gender M/F                       14/4               24/7                  10/14          χ^2^ = 9.231 p = 0.010   p = 0.977

  Mean age (SD)                    24.9 (5.0)         23.9 (4.9)            27.6 (4.6)     F = 4.140 p = 0.020      p = 1.000

  Handedness (left)                1 (5.6%)           2 (6.5%)              2 (8.3%)       χ^2^ = 0.138 p = 0.933   

  Years of education (SD)          14.11 (3.45)       13.05 (2.59)          16.00 (2.80)   F = 7.123 p = 0.002      p = 0.654

  BPRS total score (SD)            41.56 (8.00)       39.04 (9.37)          24.54 (1.10)   F = 36.971\              p = 0.807
                                                                                           p \< 0.0001              

  BPRS mood disturbance (SD)       11.22 (3.34)       9.35 (3.64)           4.50 (0.98)    F = 30.746\              p = 0.108
                                                                                           p \< 0.0001              

  BPRS negative symptoms (SD)      6.33 (2.43)        5.36 (2.78)           3.00 (0.00)    F = 13.699\              p = 0.400
                                                                                           p \< 0.0001              

  BPRS depression (SD)             4.17 (1.15)        3.23 (1.33)           1.13 (0.34)    F = 47.456\              p = 0.011[\*\*](#tf0010){ref-type="table-fn"}
                                                                                           p \< 0.0001              

  BPRS motor hyperactivity (SD)    1.00 (0.00)        1.48 (0.89)           1.00 (0.00)    *F* = 5.856\             p = 0.029[\*\*](#tf0010){ref-type="table-fn"}
                                                                                           p = 0.005                

  SANS total score (SD)            22.00 (11.55)      17.88 (14.26)         0.00 (0.00)    F = 25.721\              p = 0.674
                                                                                           p \< 0.0001              

  GAF (SD)                         62.11 (10.92)      66.0 (12.38)          88.08 (4.15)   F = 45.236\              p = 0.583
                                                                                           p \< 0.0001              

  Cigarettes smoked per day (SD)   12.83 (8.92)       5.31 (8.32)           3.25 (6.52)    F = 8.105\               p = 0.006[\*\*](#tf0010){ref-type="table-fn"}
                                                                                           p = 0.001                

  Current cannabis use             11                 8                     4              χ^2^ = 10.226\           p = 0.014[\*\*](#tf0010){ref-type="table-fn"}
                                                                                           p = 0.006                

  Current alcohol use\             3/10/5             7/21/3                1/21/2         χ^2^ = 8.125\            p = 0.253
  No/moderate/\                                                                            p = 0.087                
  uncontrolled                                                                                                      

  Days on antidepressants (SD)\    50 (47)\           None                  None                                    

  Range days                       4--170                                                                           
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: ARMS, at-risk mental state individuals; ARMS-AD, ARMS with antidepressants; ARMS-nonAD, ARMS without antidepressants; BPRS, Brief Psychiatric Rating Scale; 'BPRS depression', BPRS 3; 'BPRS motor hyperactivity', BPRS 23; 'BPRS mood disturbance', as a sum of anxiety, depression, suicidality and guilt (BPRS02, BPRS03, BPRS04 and BPRS05); 'BPRS negative symptoms' as a sum of blunted affect, emotional withdrawal, and motor retardation (BPRS16, BPRS17 and BPRS18); GAF, Global Assessment of Functioning; HC, healthy controls; SANS, Scale for the Assessment of Negative Symptoms.

Bonferroni correction (at p = 0.05) was calculated for post hoc analysis in SPSS 22.0. Only post hoc results between ARMS-AD and ARMS-nonAD groups are presented.

Significant results in post hoc analysis between ARMS-AD and ARMS-nonAD.

###### 

Between group differences in gray matter volume.

  Contrast                   Region                        p value                                            KE/radius   z value   x     y     z
  -------------------------- ----------------------------- -------------------------------------------------- ----------- --------- ----- ----- -----
  1\. Whole brain analysis                                                                                                                      
                                                           *p uncorr.*                                                                          
  ARMS \< HC                 Middle frontal gyrus          0.035                                              790         3.59      −33   57    16
  ARMS-AD \< HC              Superior frontal gyrus        0.028                                              874         3.98      −33   57    18
  ARMS-nonAD \< ARMS-AD      Left superior parietal lobe   0.023                                              944         4.33      −32   −40   45
  2\. Region of interest                                                                                                                        
                                                           *p FWE-corr*[\*](#nstbl2.1){ref-type="table-fn"}                                     
  ARMS-AD \< ARMS-nonAD      Left hippocampus              0.029                                              5 mm        2.86      −18   −19   −17
  ARMS-AD \< ARMS-nonAD      Right precuneus               0.042                                              10 mm       3.23      10    −78   51

The data presented here are from ANOVA of 3 included groups (ARMS-AD, ARMS-nonAD, HC) at a threshold of p \< 0.005 uncorrected across the whole brain.

There were no significant differences in the following contrasts: ARMS \> HC, ARMS-AD \> HC, ARMS-nonAD vs. HC, and ARMS-nonAD \> ARMS-AD.

Abbreviations: ARMS, at risk mental state; ARMS-AD, ARMS subjects currently receiving antidepressants; ARMS-nonAD, ARMS individuals without current antidepressant medication; HC, healthy controls; KE, voxels per cluster; x y z, coordinates according to the Montreal Neurological Institute.

Abbreviations: ARMS --- at-risk mental state; ARMS-AD --- ARMS with antidepressants; ARMS-nonAD --- ARMS without antidepressants; KE --- voxels per cluster.

p \< 0.0125 required.

[^1]: The two authors contributed equally.
